|By Marketwired .||
|April 1, 2014 06:00 AM EDT||
FOSTER CITY, CA -- (Marketwired) -- 04/01/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 13th Needham Healthcare Conference at 5:00 pm ET on Tuesday, April 8, 2014, at the Westin NY Grand Central Hotel in New York City.
To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live events.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets, including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
Dec. 5, 2016 09:29 AM EST Reads: 111
Dec. 5, 2016 09:15 AM EST Reads: 875
Dec. 5, 2016 09:15 AM EST Reads: 1,409
Dec. 5, 2016 08:45 AM EST Reads: 796
Dec. 5, 2016 07:30 AM EST Reads: 7,040
Dec. 5, 2016 07:30 AM EST Reads: 980
Dec. 5, 2016 07:15 AM EST Reads: 1,253
Dec. 5, 2016 06:45 AM EST Reads: 1,793
Dec. 5, 2016 06:45 AM EST Reads: 1,594
Dec. 5, 2016 06:45 AM EST Reads: 980
Dec. 5, 2016 06:30 AM EST Reads: 731
Dec. 5, 2016 06:15 AM EST Reads: 896
Dec. 5, 2016 06:00 AM EST Reads: 1,679
Dec. 5, 2016 04:30 AM EST Reads: 5,225
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, will share examples from a wide range of industries – includin...
Dec. 5, 2016 04:15 AM EST Reads: 1,617